Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-14

Clinical Trial Update: A Long-Term Safety Study of ALKS 5461 [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of ALKS 5461 for major depressive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALKS 5461 (ALKS-5461)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2018-12-14